Onkologie. 2011:5(1):28-29
Advances in targeted therapy for breast cancer
- Onkologická klinika 1. LF a VFN, Praha
The new millennium has been marked by the advent of biological targeted therapy in the treatment for breast cancer, which has gradually
worked its way from a treatment for metastatic disease to adjuvant and, most recently, neoadjuvant indications. It meets the demands
for individualization of treatment as it is intended for a small, well-defined group of patients, which guarantees its excellent efficacy. The
novel agents as well as new indications in monotherapy or in combination may take the treatment for breast cancer in a new direction
Keywords: breast cancer, biological targeted therapy, trastuzumab, lapatinib, pertuzumab, TDM1
Published: February 25, 2011 Show citation
References
- Baselga J, Bardbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase 3, randomized, open label neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Program and abstracts of the 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Texas. Abstract S3-3.
Go to original source... - Gianni L, Pienkowski T, Im YH, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase 2 study (NeoSphere). Program and abstracts of the 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Texas. Abstract S3-3. Go to original source...
- Alvarez RH, Valero V, Hortobagyi GN. Emerging Targeted Therapies for Breast Cancer, JCO July 10, 2010; 28(20): 3366-3379. Go to original source...
Go to PubMed...